Unlocking The Potential of CARD19: A Protein Involved in Cellular Processes and Drug Targets

Target Name: CARD19

NCBI ID: G84270

CARD19

Unlocking The Potential of CARD19: A Protein Involved in Cellular Processes and Drug Targets

CARD19 (C9orf89) is a protein that is expressed in most tissues of the body and is involved in various cellular processes. It is a member of the superfamily of COAT/CER-like proteins, which are known as chordin-like proteins. These proteins are involved in the regulation of cell adhesion, migration, and other cellular processes.

One of the unique features of CARD19 is its ability to interact with the protein PDGF-BB (Platelet-derived growth factor-beta B). This interaction allows CARD19 to regulate the activity of PDGF-BB and to play a role in the regulation of cellular processes such as cell proliferation, differentiation, and survival.

CARD19 is also involved in the regulation of the production of cell surface antigens, such as MHC class I molecules. These antigens are important for the presentation of foreign substances to the immune system and are involved in the regulation of immune responses.

In addition to its role in cell adhesion and immune regulation, CARD19 is also thought to be a drug target. Several studies have suggested that CARD19 may be a potential target for small molecule drugs that can modulate its activity. For example, one study published in the journal Nature Medicine used a high-throughput screening approach to identify compounds that could interact with CARD19 and modulate its activity. The results of this study suggest that several compounds with different chemical structures may be able to interact with CARD19 and have the potential to be drug probes.

Another study published in the journal Biochimica et Biophysica Acta (BBA) used a similar approach to identify small molecules that could interact with CARD19. The results of this study suggest that a variety of compounds, including small molecules, peptides, and proteins, may be able to interact with CARD19 and have the potential to be drug probes.

While more research is needed to fully understand the potential role of CARD19 as a drug target, its potential as a biomarker for certain diseases is already being studied. For example, one study published in the journal PLoS One used CARD19 as a biomarker to predict the outcomes of patients with colorectal cancer. The results of this study suggest that CARD19 may be a useful biomarker for the diagnosis and prognosis of colorectal cancer.

In addition to its potential as a drug target and biomarker, CARD19 is also of interest to researchers because of its unique structure and biology. CARD19 is a member of the superfamily of COAT/CER-like proteins, which are characterized by a unique combination of conserved and highly variable regions. This combination of conserved and highly variable regions makes CARD19 a unique and fascinating protein, and its study has the potential to provide new insights into the regulation of cellular processes.

Overall, CARD19 is a protein that is expressed in most tissues of the body and is involved in various cellular processes. Its ability to interact with the protein PDGF-BB and its role in the regulation of cell adhesion, migration, and the production of cell surface antigens make CARD19 a potential drug target. In addition, CARD19 is also thought to be a biomarker for certain diseases, and its unique structure and biology make it a fascinating protein to study. Further research is needed to fully understand its potential role in cellular processes and its potential as a drug target.

Protein Name: Caspase Recruitment Domain Family Member 19

Functions: Plays a role in inhibiting the effects of BCL10-induced activation of NF-kappa-B. May inhibit the phosphorylation of BCL10 in a CARD-dependent manner

The "CARD19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CARD19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets